- Investing Ideas
- U.S. Pharmaceuticals & Biotech Blue chip stocks
U.S. Pharmaceuticals & Biotech Blue chip stocks
Results
19
19 companies
Revvity
Market Cap: US$12.8b
Provides health sciences solutions, technologies, and services.
RVTY
US$114.24
7D
0.6%
1Y
32.1%
Biogen
Market Cap: US$30.5b
Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally.
BIIB
US$206.28
7D
-0.8%
1Y
61.5%
Revolution Medicines
Market Cap: US$41.9b
A clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers.
RVMD
US$197.81
7D
2.9%
1Y
466.0%
Waters
Market Cap: US$39.3b
Provides analytical workflow solutions in Asia, the Americas, and Europe.
WAT
US$399.70
7D
5.1%
1Y
43.8%
Charles River Laboratories International
Market Cap: US$12.7b
Charles River Laboratories International, Inc.
CRL
US$267.49
7D
15.0%
1Y
79.8%
Elanco Animal Health
Market Cap: US$13.1b
An animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide.
ELAN
US$24.20
7D
-8.5%
1Y
46.8%
Natera
Market Cap: US$39.3b
A diagnostics company, engages in the development and commercialization of molecular testing services worldwide.
NTRA
US$274.62
7D
1.8%
1Y
94.7%
Axsome Therapeutics
Market Cap: US$11.0b
A biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States.
AXSM
US$212.85
7D
-9.3%
1Y
104.0%
BioMarin Pharmaceutical
Market Cap: US$11.6b
A biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally.
BMRN
US$61.46
7D
1.5%
1Y
3.4%
ICON
Market Cap: US$12.6b
A clinical research organization, provides outsourced development and commercialization services in Ireland, Europe, the United States, and internationally.
ICLR
US$161.17
7D
-2.6%
1Y
2.1%
Alnylam Pharmaceuticals
Market Cap: US$30.6b
Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally.
ALNY
US$228.72
7D
11.3%
1Y
-47.4%
Madrigal Pharmaceuticals
Market Cap: US$11.9b
A biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States.
MDGL
US$510.36
7D
3.5%
1Y
49.1%
Insmed
Market Cap: US$21.5b
Develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally.
INSM
US$132.55
7D
30.6%
1Y
21.3%
Viatris
Market Cap: US$20.6b
Operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East.
VTRS
US$16.29
7D
-8.3%
1Y
73.5%
BeOne Medicines
Market Cap: US$37.2b
An oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally.
ONC
US$329.80
7D
2.4%
1Y
10.6%
Royalty Pharma
Market Cap: US$33.3b
Operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States.
RPRX
US$57.26
7D
-3.0%
1Y
54.7%
Merck
Market Cap: US$317.0b
Operates as a healthcare company worldwide.
MRK
US$128.37
7D
-1.1%
1Y
59.7%
Neurocrine Biosciences
Market Cap: US$16.4b
Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally.
NBIX
US$159.82
7D
-13.8%
1Y
27.2%
Gilead Sciences
Market Cap: US$163.5b
A biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.
GILD
US$130.86
7D
-0.3%
1Y
18.7%